Compare Hershey Co (HSY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Zoetis Inc — how do they compare? Hershey Co trades at $170.16 (market cap $34.83B), while Zoetis Inc trades at $75.17 (market cap $31.95B). The key difference: Hershey Co and Zoetis Inc are close in size by market cap, and Hershey Co pays the higher dividend (3.38%). Which is the better fit depends on your goals.
| HSY | ZTS | |
|---|---|---|
Market Cap | $34.83B | $31.95B |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $156.76 |
52-Week Low | $162.31 | $71.91 |
Enterprise Value | $39.63B | $39.24B |
Dividend Yield | 3.38% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $171.72, showing modest daily gains of 0.18%. The stock faces bearish technical signals with recent price action near support at $170, while fundamentals reveal mixed performance with strong earnings beats but compressed margins. Recent Q1 2026 EPS of $2.35 exceeded expectations by 15%, though net income margin declined to 7.55% in 2025 from 19.82% in 2024 due to cocoa cost pressures. The company maintains solid cash flow generation with $2.28B operating cash flow in 2025.
Hershey presents a cautious opportunity as margin recovery begins in Q2 2026, with analyst consensus target of $208.42 offering 21% upside. However, volume concerns and competitive pressures pose near-term risks. The 3.3% dividend yield provides income support while investors await evidence of sustained sales volume recovery and margin expansion in upcoming earnings.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
